pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

MedCity News

JUNE 14, 2023

2seventy Bio reported that an acute myeloid leukemia patient treated with its experimental cell therapy has died, prompting research partner Seattle Children’s Research Institute to pause the Phase 1 study. The FDA has been notified and an investigation is underway.

Leads 94

Leads Patients FDA Biopharma 94

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 113

FDA Leads Pharmaceutical Patients 113

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Claudin 18.2 Other companies developing claudin 18.2-targeted

Leads 57

Leads Biopharma Prospecting Patients 57

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies.

Medicine 96

Medicine Manufacturing Biopharma Engineering 96

Pharmaceutical Technology

MAY 24, 2023

Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Menarini Industrie Farmaceutiche Riunite.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

European Pharmaceutical Review

OCTOBER 4, 2023

Eli Lilly and Company has agreed to acquire the radiopharmaceutical firm POINT Biopharma Global for $1.4 POINT’s lead programmes are currently in late-stage development. It is being investigated for patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on hormonal treatment.

Biopharma 96

Biopharma Medicine Leads Manufacturing 96

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111

Biopharma Pharma Marketing Management 111

MedCity News

APRIL 24, 2023

A clinical trial for a Foghorn Therapeutics cancer drug is under a partial FDA hold after a patient in the early-stage study developed a cardiovascular complication. It’s the biotech’s second partial hold in the past year.

FDA 96

FDA Leads Patients Biopharma 96

PM360

SEPTEMBER 15, 2022

The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?

Patients 98

Patients Healthcare Healthcare Marketing 98

MedCity News

MARCH 7, 2023

BioMarin Pharmaceutical’s submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.

FDA 100

FDA Leads Pharmaceutical Patients 100

MedCity News

MAY 29, 2023

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads 107

Leads Patients Biopharma Pharma 107

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.

Patients 59

Patients Pharma Education Media 59

pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance.

Marketing 96

Marketing Sales Medical Patients 96

Impetus Digital

MARCH 15, 2024

In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

Pharmaceutical Technology

MAY 23, 2023

BioCryst Pharmaceuticals has secured marketing authorisation from the Public Health Institute (ISP) of Chile for oral, once-daily ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) attacks in patients aged 12 years and above.

Marketing 52

Marketing Biopharma Safety Pharma 52

pharmaphorum

AUGUST 4, 2022

This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks.

Recruitment 94

Recruitment Pharma Training Pharmaceutical manufacturing 94

Clarivate

NOVEMBER 13, 2023

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. A clinical outcome assessment is a measure that describes or reflects how a patient feels, functions or survives.

Patients 52

Patients Food and Drug Administration FDA Safety 52

MedCity News

JUNE 30, 2022

The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.

FDA 101

FDA Leads Safety Patients 101

PM360

OCTOBER 3, 2023

PRODUCT LAUNCH OF THE YEAR NEXTSTELLIS (Mayne Pharma and EVERSANA INTOUCH) RELAUNCH/REVITALIZATION OF THE YEAR VRAYLAR (AbbVie Inc. Director US Marketing and Patient Engagement, argenx US, Inc. Diversity/Multicultural: Anna Czene, Vice President, Corporate Communications & DEI Lead, CareDx, Inc. Cardiology: Bradley A.

Education 122

Education Marketing Media Management 122

PM360

DECEMBER 14, 2023

Moderna Joins CEPI Pandemic Preparedness Mission After making its debut in the pharma market during the COVID-19 pandemic, Moderna is preparing for the next pandemic. The pharma company has joined the Coalition for Epidemic Preparedness Innovations (CEPI) in a partnership that aims to shorten vaccine development timelines down to 100 days.

Physicians 52

Physicians Pharma Medical Patients 52

pharmaphorum

OCTOBER 20, 2022

Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. In my experience working on global biopharma brands, commercial success is built on collaboration and solid basics.

Competition 93

Competition Marketing Pharma Biopharma 93

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. PM360’s Focus On section examines examines a specific area of the life sciences industry.

Education 59

Education Physicians Healthcare Healthcare 59

Pharmaceutical Technology

JUNE 29, 2022

Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. The impact could be huge for the biopharma industry.

Specialization 118

Specialization Biopharma B2B Sales Manufacturing 118

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

Clarivate

NOVEMBER 10, 2022

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. Patient focused drug development in alopecia areata clinical trials.

Patients 52

Patients Food and Drug Administration FDA Safety 52

PM360

AUGUST 24, 2023

PM360 , a leading life sciences marketing industry trade publication, established the Trailblazer Awards in 2009 to recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. Braun Medical, Inc.

Marketing 52

Marketing Education Media Healthcare 52

pharmaphorum

OCTOBER 5, 2022

Sanofi also signed an agreement this week with TrialSpark, which specialises in acquiring “undervalued” clinical-stage drugs languishing in the pipelines of biopharma companies. The aim will be to identify promising candidates in areas of “unmet patient need.” TrialSpark alliance targets six candidates.

Biopharma 95

Biopharma Engineering Consulting Pharma 95

PM360

OCTOBER 5, 2023

In total, PM360 , a leading life sciences marketing industry trade publication, recognized 73 winners across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Education 52

Education Marketing Media Biopharma 52

pharmaphorum

DECEMBER 20, 2022

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. Although, so far efforts to bring a therapy to market have failed.

Pharmacology 52

Pharmacology Pharma Marketing Biopharma 52

Pharma Marketing Network

MARCH 30, 2023

Mary brings to the HBA 30 years of experience leading the strategic integration of corporate branding, marketing, health equity, inclusion, and digital innovation for biopharma, healthcare, and media companies. In 2022, she co-created Real Chemistry’s first Real Health Equity Summit “Changing Out Loud” during the J.P.

Healthcare 52

Healthcare Healthcare Biopharma Networking 52

PM360

MAY 2, 2023

We are fortunate to work with innovative startup and mid-stage biopharma companies that are developing vaccines and medicines for rare diseases, cancer, specialty therapeutic areas, and other patient needs, as well as partnering with diagnostic and medical device companies.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Biopharma 52

pharmaphorum

SEPTEMBER 30, 2022

Perhaps more interestingly, similar signals have also emerged from traditional biopharma heavyweights, such as Novartis and Lilly, which one would typically associate with more conservative approaches to pricing. New manufacturers, such as EQRx, have been vocal in their desire to bring new PD-1/PD-L1 checkpoint inhibitors (e.g.

Consulting 86

Consulting Marketing Pharma Manufacturing 86

Clarivate

MAY 8, 2023

That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. You have to be patiently impatient,” he said. Timing is everything.

Biopharma 52

Biopharma Sales Networking Pharma 52

Pharmaceutical Technology

NOVEMBER 4, 2022

Any reduced availability of medicines has a significant impact on patient care. As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The CMO solution.

Biopharma 52

Biopharma Manufacturing Media Pharmaceutical 52

pharmaphorum

SEPTEMBER 13, 2022

The HARMONY study compared two doses of Akero’s FGF21 mimic efruxifermin to placebo over 24 weeks in 128 adult patients with biopsy-confirmed NASH, a serious form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people and which for several years has been billed as one of pharma’s next big growth areas.

Biopharma 52

Biopharma Patients FDA Pharma 52

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 Up to 12.5% billion in 2029.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52